Lupin Q1 FY25 profit up 77% at Rs. 801 Cr

Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore

Lupin completes successful Phase 3 trials for Lucentis biosimilar

The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions

Lupin receives EIR from US FDA for its Somerset manufacturing facility

The facility was inspected from May 7 to May 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,

USFDA inspection of Lupin’s Nagpur injectable facility with zero 483 observations

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

Lupin appoints Christoph Funke as Chief Technical Operations Officer

Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science

Lupin launches Vilfuro-G for COPD Management in India

Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide